Cisplatin exhibits superiority over MMC as a perfusion agent in a peritoneal mesothelioma patient specific organoid HIPEC platform

Peritoneal mesothelioma (PM) is a rare malignancy with poor prognosis, representing about 10–15% of all mesothelioma cases. Herein we apply PM patient-derived tumor organoids (PTOs) in elucidating personalized HIPEC responses to bypass rarity of disease in generating preclinical data. Specimens were...

Descripción completa

Detalles Bibliográficos
Autores principales: Forsythe, Steven D., Erali, Richard A., Edenhoffer, Nicholas, Meeker, William, Wajih, Nadeem, Schaaf, Cecilia R., Laney, Preston, Vanezuela, Cristian D., Li, Wencheng, Levine, Edward A., Soker, Shay, Votanopoulos, Konstantinos I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356916/
https://www.ncbi.nlm.nih.gov/pubmed/37468581
http://dx.doi.org/10.1038/s41598-023-38545-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356916/
https://www.ncbi.nlm.nih.gov/pubmed/37468581
http://dx.doi.org/10.1038/s41598-023-38545-4

Ejemplares similares